According to the median signature risk score, the 113 HER2-positive breast cancer samples from TCGA were divided into high-risk and low-risk groups with significant overall survival differences (p < 0.0001), and the ROC curve showed that the 3-year survival rates were predicted with high accuracy (AUC = 0.980) (Figure 6). This evidence concerns the gene ERBB2 and breast cancer.